Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Treatment-related mortality and recurrence of disease account for the majority of treatment
failures in allogeneic transplantation for advanced hematologic malignancies. The most
commonly utilized conditioning regimens consist of cyclophosphamide and total-body
irradiation or busulfan and cyclophosphamide. Other agents such as etoposide or thiotepa are
sometimes added to maximize the antileukemic effect. New conditioning regimens are however
still needed to maximize efficacy and limit treatment-related deaths. Over the past several
years, the investigators have evaluated several new conditioning regimens that incorporate
fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic
activity with alkylating agents. Recent data have suggested that fludarabine may be used in
combination with standard doses of oral or IV busulfan, thus reducing the toxicity
previously observed with cyclophosphamide/ busulfan regimens.
Interventional
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the rate of engraftment.
Up to 30 days post-transplant
Yes
Damiano Rondelli, MD
Principal Investigator
University of Illinois
United States: Institutional Review Board
2000-0117
NCT01499147
February 2000
February 2015
Name | Location |
---|---|
University of Illinois at Chicago Medical Center | Chicago, Illinois 60612 |